Sangamo Therapeutics Inc. [NASDAQ: SGMO] stock went on a downward path that fall over -0.87% on Tuesday, amounting to a one-week price increase of more than 14.06%. The company report on July 30, 2020 that Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders.
– Collaboration for gene regulation therapies for three neurodevelopmental targets, including for genes linked to autism spectrum disorder and intellectual disability.
– Sangamo will receive a $75M upfront licensing fee and is eligible to receive up to $720M in potential milestones, as well as royalties on potential net commercial sales.
Over the last 12 months, SGMO stock rose by 1.60%. The average equity rating for SGMO stock is currently 2.20, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.69 billion, with 116.06 million shares outstanding and 116.00 million shares in the current float. Compared to the average trading volume of 2.27M shares, SGMO stock reached a trading volume of 1217730 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Sangamo Therapeutics Inc. [SGMO]:
SunTrust have made an estimate for Sangamo Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 07, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on August 26, 2019, representing the official price target for Sangamo Therapeutics Inc. stock.
The Average True Range (ATR) for Sangamo Therapeutics Inc. is set at 0.60, with the Price to Sales ratio for SGMO stock in the period of the last 12 months amounting to 15.71. The Price to Book ratio for the last quarter was 3.36, with the Price to Cash per share for the same quarter was set at 2.43.
SGMO Stock Performance Analysis:
Sangamo Therapeutics Inc. [SGMO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.06. With this latest performance, SGMO shares gained by 16.38% in over the last four-week period, additionally plugging by 54.80% over the last 6 months – not to mention a rise of 1.60% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SGMO stock in for the last two-week period is set at 56.09, with the RSI for the last a single of trading hit 58.25, and the three-weeks RSI is set at 56.34 for Sangamo Therapeutics Inc. [SGMO]. The present Moving Average for the last 50 days of trading for this stock 10.60, while it was recorded at 11.01 for the last single week of trading, and 8.91 for the last 200 days.
Insight into Sangamo Therapeutics Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Sangamo Therapeutics Inc. [SGMO] shares currently have an operating margin of -102.69. Sangamo Therapeutics Inc.’s Net Margin is presently recorded at -92.93.
Return on Total Capital for SGMO is now -24.12, given the latest momentum, and Return on Invested Capital for the company is -21.93. Return on Equity for this stock declined to -23.82, with Return on Assets sitting at -15.50. When it comes to the capital structure of this company, Sangamo Therapeutics Inc. [SGMO] has a Total Debt to Total Equity ratio set at 10.27. Additionally, SGMO Total Debt to Total Capital is recorded at 9.31, with Total Debt to Total Assets ending up at 6.97. Long-Term Debt to Equity for the company is recorded at 9.52, with the Long-Term Debt to Total Capital now at 8.64.
Reflecting on the efficiency of the workforce at the company, Sangamo Therapeutics Inc. [SGMO] managed to generate an average of -$268,887 per employee. Receivables Turnover for the company is 4.80 with a Total Asset Turnover recorded at a value of 0.17.Sangamo Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.00 and a Current Ratio set at 6.00.
SGMO Stock EPS
With the latest financial reports released by the company, Sangamo Therapeutics Inc. posted -0.26/share EPS, while the average EPS was predicted by analysts to be reported at -0.36/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 27.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SGMO.
Sangamo Therapeutics Inc. [SGMO] Insider Position Details
There are presently around $839 million, or 54.00% of SGMO stock, in the hands of institutional investors. The top three institutional holders of SGMO stocks are: BLACKROCK INC. with ownership of 9,377,336, which is approximately -1.646% of the company’s market cap and around 0.60% of the total institutional ownership; VANGUARD GROUP INC, holding 8,554,638 shares of the stock with an approximate value of $97.86 million in SGMO stocks shares; and WASATCH ADVISORS INC, currently with $67.94 million in SGMO stock with ownership of nearly -20.684% of the company’s market capitalization.
Positions in Sangamo Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 90 institutional holders increased their position in Sangamo Therapeutics Inc. [NASDAQ:SGMO] by around 11,636,484 shares. Additionally, 84 investors decreased positions by around 16,244,651 shares, while 46 investors held positions by with 45,490,306 shares. The mentioned changes placed institutional holdings at 73,371,441 shares, according to the latest SEC report filing. SGMO stock had 28 new institutional investments in for a total of 6,587,364 shares, while 27 institutional investors sold positions of 10,435,096 shares during the same period.